Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?

被引：0
作者：
Gianni, Caterina [1 ]
Nicolo, Eleonora [2 ]
Cristofanilli, Massimo [2 ]
机构：
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Dept Med Oncol, Breast & GYN Unit, Meldola, Italy
[2] Weill Cornell Med, Div Hematol Oncol, Dept Med, 1300 York Ave, New York, NY 10065 USA
来源：
TRANSLATIONAL BREAST CANCER RESEARCH | 2024年 / 5卷
关键词：
CDK4/6; inhibitors; early breast cancer (EBC); ribociclib; hormone receptor positive (HR+); PLUS ENDOCRINE THERAPY; PALBOCICLIB;
D O I：
10.21037/tbcr-24-41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 24 条
  • [1] Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
    Burris, Howard A.
    Chan, Arlene
    Bardia, Aditya
    Thaddeus Beck, J.
    Sohn, Joohyuk
    Neven, Patrick
    Tripathy, Debu
    Im, Seock-Ah
    Chia, Stephen
    Esteva, Francisco J.
    Hart, Lowell
    Zarate, Juan Pablo
    Ridolfi, Antonia
    Lorenc, Karen Rodriguez
    Yardley, Denise A.
    [J]. BRITISH JOURNAL OF CANCER, 2021, 125 (05) : 679 - 686
  • [2] Fasching Peter A., 2024, Annals of Oncology, V35, P1, DOI [10.1016/annonc/, DOI 10.1016/ANNONC]
  • [3] Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
    Garcia-Murillas, Isaac
    Schiavon, Gaia
    Weigelt, Britta
    Ng, Charlotte
    Hrebien, Sarah
    Cutts, Rosalind J.
    Cheang, Maggie
    Osin, Peter
    Nerurkar, Ashutosh
    Kozarewa, Iwanka
    Garrido, Javier Armisen
    Dowsett, Mitch
    Reis-Filho, Jorge S.
    Smith, Ian E.
    Turner, Nicholas C.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (302)
  • [4] Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review
    Garutti, Mattia
    Griguolo, Gaia
    Botticelli, Andrea
    Buzzatti, Giulia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Molinelli, Chiara
    Adamo, Vincenzo
    Bianchini, Giampaolo
    Biganzoli, Laura
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    Fabi, Alessandra
    Frassoldati, Antonio
    Gennari, Alessandra
    Marchio, Caterina
    Perrone, Francesco
    Viale, Giuseppe
    Zamagni, Claudio
    Zambelli, Alberto
    Del Mastro, Lucia
    De Placido, Sabino
    Guarneri, Valentina
    Marchetti, Paolo
    Puglisi, Fabio
    [J]. CANCERS, 2022, 14 (08)
  • [5] Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
    Gnant, Michael
    Dueck, Amylou C.
    Frantal, Sophie
    Martin, Miguel
    Burstein, Hal J.
    Greil, Richard
    Fox, Peter
    Wolff, Antonio C.
    Chan, Arlene
    Winer, Eric P.
    Pfeiler, Georg
    Miller, Kathy D.
    Colleoni, Marco
    Suga, Jennifer M.
    Rubovsky, Gabor
    Bliss, Judith M.
    Mayer, Ingrid A.
    Singer, Christian F.
    Nowecki, Zbigniew
    Hahn, Olwen
    Thomson, Jacqui
    Wolmark, Norman
    Amillano, Kepa
    Rugo, Hope S.
    Steger, Guenther G.
    Hernando Fernandez de Aranguiz, Blanca
    Haddad, Tufia C.
    Perello, Antonia
    Bellet, Meritxell
    Fohler, Hannes
    Metzger Filho, Otto
    Jallitsch-Halper, Anita
    Solomon, Kadine
    Schurmans, Celine
    Theall, Kathy P.
    Lu, Dongrui R.
    Tenner, Kathleen
    Fesl, Christian
    DeMichele, Angela
    Mayer, Erica L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 282 - +
  • [6] How I treat endocrine-dependent metastatic breast cancer
    Gombos, A.
    Goncalves, A.
    Curigliano, G.
    Bartsch, R.
    Kyte, J. A.
    Ignatiadis, M.
    Awada, A.
    [J]. ESMO OPEN, 2023, 8 (02)
  • [7] Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
    Hortobagyi, Gabriel
    Stroyakovsky, Daniil
    Yardley, Denise
    Huang, Chiun-Shen
    Fasching, Peter A.
    Crown, John
    Bardia, Aditya
    Chia, Stephen
    Im, Seock-Ah
    Martin, Miguel
    Loi, Sherene
    Xu, Binghe
    Hurvitz, Sara
    Barrios, Carlos
    Untch, Michael
    Moroose, Rebecca
    Visco, Frances
    Parnizari, Federico
    Ghaznawi, Farhat
    Li, Zheng
    Waters, Sorcha
    Chakravartty, Arunava
    Slamon, Dennis
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [8] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
    Johnston, Stephen R. D.
    Toi, Masakazu
    O'Shaughnessy, Joyce
    Rastogi, Priya
    Campone, Mario
    Neven, Patrick
    Huang, Chiun-Sheng
    Huober, Jens
    Jaliffe, Georgina Garnica
    Cicin, Irfan
    Tolaney, Sara M.
    Goetz, Matthew P.
    Rugo, Hope S.
    Senkus, Elzbieta
    Testa, Laura
    Del Mastro, Lucia
    Shimizu, Chikako
    Wei, Ran
    Shahir, Ashwin
    Munoz, Maria
    San Antonio, Belen
    Andre, Valerie
    Harbeck, Nadia
    Martin, Miguel
    [J]. LANCET ONCOLOGY, 2023, 24 (01) : 77 - 90
  • [9] The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis
    Lee, Kirsty Wai Chung
    Lord, Sally
    Finn, Richard S.
    Lim, Elgene
    Martin, Andrew
    Loi, Sherene
    Lynch, Jodi
    Friedlander, Michael
    Lee, Chee Khoon
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (01) : 271 - 278
  • [10] Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
    Lloyd, Maxwell R.
    Spring, Laura M.
    Bardia, Aditya
    Wander, Seth A.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (05) : 821 - 830
123